» Articles » PMID: 28232751

CLK-dependent Exon Recognition and Conjoined Gene Formation Revealed with a Novel Small Molecule Inhibitor

Abstract

CDC-like kinase phosphorylation of serine/arginine-rich proteins is central to RNA splicing reactions. Yet, the genomic network of CDC-like kinase-dependent RNA processing events remains poorly defined. Here, we explore the connectivity of genomic CDC-like kinase splicing functions by applying graduated, short-exposure, pharmacological CDC-like kinase inhibition using a novel small molecule (T3) with very high potency, selectivity, and cell-based stability. Using RNA-Seq, we define CDC-like kinase-responsive alternative splicing events, the large majority of which monotonically increase or decrease with increasing CDC-like kinase inhibition. We show that distinct RNA-binding motifs are associated with T3 response in skipped exons. Unexpectedly, we observe dose-dependent conjoined gene transcription, which is associated with motif enrichment in the last and second exons of upstream and downstream partners, respectively. siRNA knockdown of CLK2-associated genes significantly increases conjoined gene formation. Collectively, our results reveal an unexpected role for CDC-like kinase in conjoined gene formation, via regulation of 3'-end processing and associated splicing factors.The phosphorylation of serine/arginine-rich proteins by CDC-like kinase is a central regulatory mechanism for RNA splicing reactions. Here, the authors synthesize a novel small molecule CLK inhibitor and map CLK-responsive alternative splicing events and discover an effect on conjoined gene transcription.

Citing Articles

Function of serine/arginine-rich splicing factors in hematopoiesis and hematopoietic malignancies.

Zhang H, Zhu H, Peng H, Sheng Y Cancer Cell Int. 2024; 24(1):257.

PMID: 39034387 PMC: 11265194. DOI: 10.1186/s12935-024-03438-7.


Exon inclusion signatures enable accurate estimation of splicing factor activity.

Anglada-Girotto M, Moakley D, Zhang C, Miravet-Verde S, Califano A, Serrano L bioRxiv. 2024; .

PMID: 38979366 PMC: 11230296. DOI: 10.1101/2024.06.21.600051.


2-Desaza-annomontine (C81) impedes angiogenesis through reduced VEGFR2 expression derived from inhibition of CDC2-like kinases.

Zech T, Wolf A, Hector M, Bischoff-Kont I, Krishnathas G, Kuntschar S Angiogenesis. 2024; 27(2):245-272.

PMID: 38403816 PMC: 11021337. DOI: 10.1007/s10456-024-09906-y.


SGC-CLK-1: A chemical probe for the Cdc2-like kinases CLK1, CLK2, and CLK4.

Tiek D, Wells C, Schroder M, Song X, Alamillo-Ferrer C, Goenka A Curr Res Chem Biol. 2023; 3.

PMID: 38009092 PMC: 10673624. DOI: 10.1016/j.crchbi.2023.100045.


Target 2035 - an update on private sector contributions.

Ackloo S, Antolin A, Bartolome J, Beck H, Bullock A, Betz U RSC Med Chem. 2023; 14(6):1002-1011.

PMID: 37360399 PMC: 10285765. DOI: 10.1039/d2md00441k.


References
1.
Araki S, Dairiki R, Nakayama Y, Murai A, Miyashita R, Iwatani M . Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing. PLoS One. 2015; 10(1):e0116929. PMC: 4291223. DOI: 10.1371/journal.pone.0116929. View

2.
Eirew P, Steif A, Khattra J, Ha G, Yap D, Farahani H . Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature. 2014; 518(7539):422-6. PMC: 4864027. DOI: 10.1038/nature13952. View

3.
Gerstberger S, Hafner M, Tuschl T . A census of human RNA-binding proteins. Nat Rev Genet. 2014; 15(12):829-45. PMC: 11148870. DOI: 10.1038/nrg3813. View

4.
Terao Y, Suzuki H, Yoshikawa M, Yashiro H, Takekawa S, Fujitani Y . Design and biological evaluation of imidazo[1,2-a]pyridines as novel and potent ASK1 inhibitors. Bioorg Med Chem Lett. 2012; 22(24):7326-9. DOI: 10.1016/j.bmcl.2012.10.084. View

5.
Dominguez D, Tsai Y, Weatheritt R, Wang Y, Blencowe B, Wang Z . An extensive program of periodic alternative splicing linked to cell cycle progression. Elife. 2016; 5. PMC: 4884079. DOI: 10.7554/eLife.10288. View